Researchers at the University of Tokyo have 2 in regenerative medicine: the creation of fully functional kidneys from induced pluripotent stem cells (iPSCs) that successfully function after transplantation in pigs. This accomplishment brings us closer to solving the organ shortage crisis.
The study, 1 in Cell Stem Cell, demonstrates that lab-grown kidneys can filter blood, produce urine, and integrate with the recipient vascular system—functions that had proved elusive in previous organoid research.
The Organ Shortage Crisis
Over 800,000 people worldwide live with end-stage renal disease, requiring dialysis or transplantation to survive. Yet only about 25,000 kidney transplants are performed annually in the United States, with waiting lists stretching to 5-7 years. Many patients die waiting. Growing replacement organs from a patient own cells could eliminate wait lists, remove the need for immunosuppressive drugs, and provide organs of ideal compatibility.
Technical Achievement
Creating a functional kidney is extraordinarily complex—the organ contains over 20 specialized cell types arranged in intricate structures. Previous lab-grown kidney organoids functioned at the cellular level but lacked the architecture for actual filtration. The Tokyo team breakthrough came from a novel scaffolding approach: they used decellularized pig kidneys—real kidneys stripped of their cells but retaining the structural framework—as a template for iPSC-derived cells to populate and organize.
Results in Pigs
The lab-grown kidneys achieved 65% of normal glomerular filtration rate, with successful concentration and excretion of waste products. The organs connected properly to recipient blood supply, and when using recipient-derived iPSCs, there was minimal rejection. Function was maintained for 8 weeks at study endpoint.
Path to Human Application
While exciting, significant work remains before human trials. The team must demonstrate long-term function, scale production, and ensure safety. Dr. Takashi Yokoo, senior author, estimates 5-7 years before clinical trials could begin. "The kidney is arguably the hardest organ to bioengineer," notes Dr. Yokoo. "If we can do this, it opens the door for other organs—liver, heart, lungs."
Implications for Longevity
For the aging population, kidney function declines predictably with age. The ability to replace failing organs with young, healthy tissue grown from one own cells could effectively turn back the clock on one of aging most serious consequences. Several biotech companies are racing to commercialize similar approaches: Miromatrix is developing bioengineered pig organs, Organovo focuses on 3D-printed tissues, and United Therapeutics combines xenotransplantation with bioengineering approaches.
